{"id":"https://openalex.org/W2736788481","doi":null,"title":"MM-121: a human monoclonal antibody ErbB3 antagonist","display_name":"MM-121: a human monoclonal antibody ErbB3 antagonist","publication_year":2008,"publication_date":"2008-05-01","ids":{"openalex":"https://openalex.org/W2736788481","mag":"2736788481"},"language":"en","primary_location":{"id":"mag:2736788481","doi":null,"is_oa":false,"landing_page_url":"http://cancerres.aacrjournals.org/content/68/9_Supplement/3974","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087864188","display_name":"Birgit Schoeberl","orcid":"https://orcid.org/0000-0002-1990-5315","observed_orcids":["https://orcid.org/0000-0002-1990-5315"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Birgit Schoeberl","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":"https://orcid.org/0000-0002-1990-5315","affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046123085","display_name":"Kip A. West","orcid":"https://orcid.org/0000-0002-3891-0830","observed_orcids":["https://orcid.org/0000-0002-3891-0830"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kip A. West","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":"https://orcid.org/0000-0002-3891-0830","affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061281636","display_name":"Magdalena Leszczyniecka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Magdalena Leszczyniecka","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100533073","display_name":"Lin Nie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lin Nie","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007244834","display_name":"Olga V. Burenkova","orcid":"https://orcid.org/0000-0002-9440-6276","observed_orcids":["https://orcid.org/0000-0002-9440-6276"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olga Burenkova","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":"https://orcid.org/0000-0002-9440-6276","affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014695559","display_name":"Bryan E. Linggi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Linggi","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027620289","display_name":"Aaron Fulgham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron Fulgham","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113850128","display_name":"Art J. Kudla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Art Kudla","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joe Toth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joe Toth","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081877228","display_name":"Violette B. Paragas","orcid":"https://orcid.org/0000-0001-9473-8767","observed_orcids":["https://orcid.org/0000-0001-9473-8767"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Violette Paragas","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":"https://orcid.org/0000-0001-9473-8767","affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065331760","display_name":"Lihui Xu","orcid":"https://orcid.org/0000-0002-3113-4541","observed_orcids":["https://orcid.org/0000-0002-3113-4541"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lihui Xu","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":"https://orcid.org/0000-0002-3113-4541","affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043771907","display_name":"Viara Grantcharova","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Viara Grantcharova","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085157263","display_name":"Raghida A. Bukhalid","orcid":"https://orcid.org/0009-0006-5407-8913","observed_orcids":["https://orcid.org/0009-0006-5407-8913"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raghida Bukhalid","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050734207","display_name":"Washington Alves","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Washington Alves","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071417089","display_name":"Matt Wallace","orcid":"https://orcid.org/0000-0003-4842-0998","observed_orcids":["https://orcid.org/0000-0003-4842-0998"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matt Wallace","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084930714","display_name":"J.N. Varghese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J.N. Varghese","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016499017","display_name":"Mike Feldhaus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike Feldhaus","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034804804","display_name":"Aparna Kumar","orcid":"https://orcid.org/0000-0002-2828-7010","observed_orcids":["https://orcid.org/0000-0002-2828-7010"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aparna Kumar","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109881019","display_name":"Jonathan B. Fitzgerald","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan B. Fitzgerald","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108833343","display_name":"Emily A. Pace","orcid":"https://orcid.org/0009-0006-0244-3456","observed_orcids":["https://orcid.org/0009-0006-0244-3456"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Pace","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072632371","display_name":"William J. Slichenmyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William J. Slichenmyer","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074616498","display_name":"Ulrik B. Nielsen","orcid":"https://orcid.org/0000-0001-7198-1924","observed_orcids":["https://orcid.org/0000-0001-7198-1924"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ulrik B. Nielsen","raw_affiliation_strings":["Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":"https://orcid.org/0000-0001-7198-1924","affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210124791"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"68","issue":null,"first_page":"3974","last_page":"3974"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her3","display_name":"HER3","score":0.9399999976158142},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8740000128746033},{"id":"https://openalex.org/keywords/erbb-signaling-pathway","display_name":"ErbB signaling","score":0.7620000243186951},{"id":"https://openalex.org/keywords/erbb-receptors","display_name":"ErbB receptors","score":0.5540000200271606},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.6230000257492065},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":1.0},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/xenograft-tumor-growth","display_name":"xenograft tumor growth","score":0.7850000262260437},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8299999833106995},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8019999861717224},{"id":"https://openalex.org/keywords/preclinical-safety-evaluation","display_name":"preclinical safety","score":0.4880000054836273}],"concepts":[{"id":"https://openalex.org/C115456853","wikidata":"https://www.wikidata.org/wiki/Q17917132","display_name":"ERBB3","level":4,"score":0.8486129641532898},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6742227077484131},{"id":"https://openalex.org/C2779251935","wikidata":"https://www.wikidata.org/wiki/Q5385089","display_name":"ErbB","level":3,"score":0.6555522084236145},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5698993802070618},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5332094430923462},{"id":"https://openalex.org/C185323287","wikidata":"https://www.wikidata.org/wiki/Q59252204","display_name":"Neuregulin","level":3,"score":0.529119610786438},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5254796147346497},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5002119541168213},{"id":"https://openalex.org/C2778560701","wikidata":"https://www.wikidata.org/wiki/Q14914188","display_name":"Neuregulin 1","level":3,"score":0.48709845542907715},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4735000729560852},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3888949751853943},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3761866092681885},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30079835653305054},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.25671350955963135},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.243391215801239},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22170987725257874},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2736788481","doi":null,"is_oa":false,"landing_page_url":"http://cancerres.aacrjournals.org/content/68/9_Supplement/3974","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2316995532","https://openalex.org/W2569188130","https://openalex.org/W2120213327","https://openalex.org/W2318262039","https://openalex.org/W1968083457","https://openalex.org/W2151464858","https://openalex.org/W2561218376","https://openalex.org/W1979056373","https://openalex.org/W2213828346","https://openalex.org/W2601086841"],"abstract_inverted_index":{"3974":[0],"The":[3],"role":[4,94],"of":[5,17,43,78,142,171,184,197,265,273,289],"the":[6,18,44,54,120,287],"EGFR":[7,24,99],"family":[8],"in":[9,53,86,95,115,146,156,167,195,242,262,270],"cancer":[10,148,290],"is":[11],"well":[12],"documented.":[13],"To":[14],"date":[15],"most":[16],"attention":[19],"has":[20,69],"been":[21,71],"focused":[22],"on":[23],"and":[25,37,57,83,100,113,126,179,221,233,245,268,291],"ErbB2.":[26],"We":[27],"have":[28,282],"taken":[29],"a":[30,39,61,92,160,224],"systems":[31],"approach":[32],"to":[33,98,122,132,163,213,229],"understanding":[34],"ErbB":[35,55,266],"signaling":[36,144,267],"built":[38],"comprehensive":[40],"computational":[41],"model":[42],"pathway.":[45],"Simulations":[46],"revealed":[47],"ErbB3":[48,68,109,124,198,214],"as":[49,60,73],"an":[50,74,231],"ultra-sensitive":[51],"node":[52],"pathway":[56],"suggested":[58,209],"it":[59],"better":[62],"target":[63,76],"for":[64,119,286],"therapeutic":[65],"intervention.":[66],"Historically,":[67],"not":[70],"considered":[72],"attractive":[75],"because":[77],"its":[79],"impaired":[80],"kinase":[81],"activity":[82,125,199],"low":[84],"expression":[85],"tumors":[87],"although":[88],"recent":[89],"publications":[90],"suggest":[91,250],"key":[93],"promoting":[96],"resistance":[97],"ErbB2":[101],"targeted":[102],"therapeutics.\u2028":[103],"Human":[104],"monoclonal":[105],"IgG2":[106],"antibodies":[107],"against":[108],"were":[110,239],"then":[111],"developed":[112],"tested":[114],"multiple":[116,168],"orthogonal":[117],"assays":[118],"ability":[121,162],"modulate":[123],"one":[127],"candidate,":[128],"MM-121,":[129],"was":[130,154],"chosen":[131],"move":[133],"forward":[134,294],"into":[135,295],"pre-clinical":[136,237],"testing.":[137],"MM-121":[138,152,158,192,211,252,280],"demonstrated":[139],"potent":[140],"inhibition":[141,196,264],"heregulin-induced":[143],"events":[145],"human":[147,172,222],"cell":[149],"lines.\u2028":[150],"When":[151],"efficacy":[153,269],"assessed":[155],"vivo,":[157],"showed":[159,189],"dose-dependent":[161],"inhibit":[164],"tumor":[165],"growth":[166],"xenograft":[169,271],"models":[170,272],"cancer,":[173],"including":[174],"ovarian,":[175],"renal":[176],"cell,":[177],"pancreatic":[178],"prostate":[180],"cancer.":[181],"Pharmacodynamic":[182],"analysis":[183],"samples":[185],"from":[186,216],"these":[187,276],"studies":[188,208,238,249],"that":[190,210,251,260,279],"chronic":[191],"administration":[193],"resulted":[194],"which":[200],"correlated":[201],"with":[202,223],"efficacy.\u2028":[203],"In":[204,227],"vitro":[205],"antibody":[206],"binding":[207],"binds":[212],"receptors":[215],"mouse,":[217,243],"rat,":[218],"cynomolgus":[219,246],"monkey":[220],"similar":[225],"affinity.":[226],"order":[228],"design":[230],"efficacious":[232],"safe":[234],"dosing":[235],"regimen,":[236],"carried":[240],"out":[241],"rat":[244],"monkey.":[247],"These":[248],"can":[253],"safely":[254],"be":[255],"administered":[256],"at":[257],"serum":[258],"levels":[259],"produce":[261],"good":[263],"cancer.\u2028":[274],"Cumulatively,":[275],"data":[277],"support":[278],"could":[281],"significant":[283],"clinical":[284,298],"benefit":[285],"treatment":[288],"warrant":[292],"proceeding":[293],"phase":[296],"1":[297],"trials.":[299]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-07-31T00:00:00"}